GREM1-AS1: A Potential Drug Target and Biomarker (G100131315)

Target Name: GREM1-AS1

NCBI ID: G100131315

GREM1-AS1

Other Name(s): GREM1 antisense RNA 1

GREM1-AS1: A Potential Drug Target and Biomarker

GREM1-AS1, also known as Gremlin-1, is a protein that is expressed in various tissues and cells throughout the body. It is a glycoprotein that consists of two heavy chains and two light chains. GREM1-AS1 has been identified as a potential drug target and biomarker due to its unique structure and expression pattern in various tissues.

The protein encoded by GREM1-AS1 is composed of 154 amino acids, and its molecular weight is approximately 17 kDa. GREM1-AS1 is predominantly expressed in the brain, heart, and kidneys, with lower levels of expression found in the liver, muscle, and fat. The protein is expressed in a unique manner, with the first two heavy chains being expressed in the brain and the second two heavy chains being expressed in the heart and kidneys.

GREM1-AS1 has been shown to play a critical role in various physiological processes, including cell adhesion, migration, and signaling. It is a key regulator of the Notch signaling pathway, which is involved in the regulation of stem cell proliferation and differentiation. In addition, GREM1-AS1 has been shown to play a role in the regulation of ion channels, which are responsible for the flow of electrical current through cells.

GREM1-AS1 has also been shown to be involved in the development and progression of various diseases, including neurodegenerative disorders, cancer, and cardiovascular disease. For example, studies have shown that GREM1-AS1 is overexpressed in the brains of individuals with Alzheimer's disease, and that it is involved in the regulation of neuroprotective enzymes. In addition, GREM1-AS1 has been shown to be involved in the development of cancer, with studies showing that it is overexpressed in various types of cancer.

GREM1-AS1 has also been shown to be a potential biomarker for various diseases, including neurodegenerative disorders, cancer, and cardiovascular disease. For example, studies have shown that GREM1-AS1 is downregulated in individuals with Alzheimer's disease, and that it is involved in the regulation of neuroprotective enzymes. In addition, GREM1-AS1 has been shown to be involved in the development of cancer, with studies showing that it is overexpressed in various types of cancer.

In conclusion, GREM1-AS1 is a protein that has been identified as a potential drug target and biomarker. Its unique structure and expression pattern, as well as its involvement in various physiological processes and diseases, make it an attractive target for further research and development. Further studies are needed to fully understand the role of GREM1-AS1 in various biological processes and to determine its potential as a drug target and biomarker.

Protein Name: GREM1 Antisense RNA 1

The "GREM1-AS1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about GREM1-AS1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets